Therapy of leptomeningeal metastasis in solid tumors

Cancer Treatment Reviews

Volumn 43, Issue , 2016, Pages 83-91

  Mack, F ^a   Baumert, B G ^a   Schafer N ^a   Hattingen, E ^a   Scheffler, B ^a   Herrlinger, U ^a   Glas, M ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Intrathecal chemotherapy; Leptomeningeal carcinomatosis; Leptomeningeal metastasis; WBRT

Indexed keywords

CAPECITABINE; CARMUSTINE; CORTICOSTEROID; CYTARABINE; DABRAFENIB; DEXAMETHASONE; ETOPOSIDE; FOLINIC ACID; GEMCITABINE; IPILIMUMAB; LAPATINIB; LOMUSTINE; MAFOSFAMIDE; METHOTREXATE; NITROSOUREA; PREDNISOLONE; RITUXIMAB; TAMOXIFEN; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TRASTUZUMAB; VEMURAFENIB; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARACHNOIDITIS; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL FEATURE; COGNITIVE DEFECT; CRANIAL NERVE PARALYSIS; DISEASE CONTROL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; HEADACHE; HISTOPATHOLOGY; HUMAN; INTRACRANIAL HYPERTENSION; LEPTOMENINX; LEUKOENCEPHALOPATHY; MELANOMA; MENINGEAL METASTASIS; MENINGITIS; NAUSEA AND VOMITING; NEUROTOXICITY; NON SMALL CELL LUNG CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; RADICULOPATHY; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; SUBARACHNOID SPACE; SYMPTOM; SYSTEMIC DISEASE; TUMOR SEEDING; CANCER STAGING; CEREBROSPINAL FLUID; INTRASPINAL DRUG ADMINISTRATION; MENINGEAL NEOPLASMS; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RADIOTHERAPY; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CYTARABINE; HUMANS; INJECTIONS, SPINAL; MENINGEAL NEOPLASMS; METHOTREXATE; NEOPLASM SEEDING; NEOPLASM STAGING; RADIOTHERAPY; THIOTEPA; TREATMENT OUTCOME;

EID: 84962909752     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2015.12.004     Document Type: Review

References (98)

1. Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 2010, 11(9):871-879.
2. Groves M.D. Leptomeningeal disease. Neurosurg Clin N Am 2011, 22(1):67-78. [vii.].
3. Chamberlain M.C. Neoplastic meningitis. Semin Neurol 2004, 24(4):363-374.
4. Le Rhun E., Taillibert S., Chamberlain M.C. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 2013, 4(Suppl. 4):S265-S288.
5. Le Rhun E., et al. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol 2013, 113(1):83-92.
6. Yap H.Y., et al. Meningeal carcinomatosis in breast cancer. Cancer 1978, 42(1):283-286.
7. Aroney R.S., et al. Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 1981, 71(1):26-32.
8. Amer M.H., et al. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978, 42(2):660-668.
9. Bendell J.C., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97(12):2972-2977.
10. Chamberlain M.C. Neoplastic meningitis. Handb Clin Neurol 2012, 105:757-766.
11. Erlich S.S., Davis R.L. Spinal subarachnoid metastasis from primary intracranial glioblastoma multiforme. Cancer 1978, 42(6):2854-2864.
12. Yung W.A., Horten B.C., Shapiro W.R. Meningeal gliomatosis: a review of 12 cases. Ann Neurol 1980, 8(6):605-608.
13. Vertosick F.T., Selker R.G. Brain stem and spinal metastases of supratentorial glioblastoma multiforme: a clinical series. Neurosurgery 1990, 27(4):516-521. [discussion 521-2].
14. Dardis C., et al. Leptomeningeal metastases in high-grade adult glioma: development, diagnosis, management, and outcomes in a series of 34 patients. Front Neurol 2014, 5:220.
15. Mandel J.J., et al. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol 2014, 120(3):597-605.
16. Chamberlain M.C. Neoplastic meningitis. J Clin Oncol 2005, 23(15):3605-3613.
17. Balm M., Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996, 53(7):626-632.
18. Wasserstrom W.R., Glass J.P., Posner J.B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49(4):759-772.
19. Kaplan J.G., et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990, 9(3):225-229.
20. Posner J.B., Chernik N.L. Intracranial metastases from systemic cancer. Adv Neurol 1978, 19:579-592.
21. Herrlinger U., et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 2004, 223(2):167-178.
22. Prommel P., et al. Neoplastic meningitis: how MRI and CSF cytology are influenced by CSF cell count and tumor type. Sci World J 2013, 2013:248072.
23. Mittl R.L., Yousem D.M. Frequency of unexplained meningeal enhancement in the brain after lumbar puncture. AJNR Am J Neuroradiol 1994, 15(4):633-638.
24. Chamberlain M.C., Kormanik P.A. Prognostic significance of 111indium-DTPA CSF flow studies in leptomeningeal metastases. Neurology 1996, 46(6):1674-1677.
25. Glantz M.J., et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995, 75(12):2919-2931.
26. Glass J.P., et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979, 29(10):1369-1375.
27. Kranz B.R. Detection of rare malignant cells and their apoptotic fragments in cerebrospinal fluid. Lancet 2000, 356(9237):1242-1244.
28. Moldrich G., Lange P., Strik H. Carcinoembryonic antigen in the CSF of cancer patients-the value of intrathecal synthesis and correlation with IgA-diffusion dynamics. Acta Neurol Belg 2010, 110(4):314-320.
29. Groves M.D., et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 2009, 94(2):229-234.
30. Shapiro W.R., Johanson C.E., Boogerd W. Treatment modalities for leptomeningeal metastases. Semin Oncol 2009, 36(4 Suppl. 2):S46-S54.
31. Chamberlain M.C., Kormanik P.R. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 1997, 35(1):55-64.
32. Grant R., et al. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 1994, 51(5):457-461.
33. Chamberlain M., Kormanik P. Leptomeningeal metastases due to melanoma. Int J Oncol 1996, 9(3):505-510.
34. Gwak H.S., et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 2013, 8(5):599-605.
35. Kuiper J.L., et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung cancer 2015, 89(3):255-261.
36. Morris P.G., et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012, 7(2):382-385.
37. Central nervous system cancers. NCCN, v. 1.2010.
38. AWMF-Leitlinien, Hirnmetastasen und Meningeosis neoplastica. Deutsche Gesellschaft für Neurologie, 2014. 030/060.
39. Oncoline, Leptomeningeal metastases. Dutch Neuro-Oncology Working Group - Nation wide guideline, 2006, v. 1.0.
40. Andic F., et al. Dosimetric comparison of conventional helmet-field whole-brain irradiation with three-dimensional conformal radiotherapy: dose homogeneity and retro-orbital area coverage. Br J Radiol 2009, 82(974):118-122.
41. Kortmann R.D., et al. Is the standardized helmet technique adequate for irradiation of the brain and the cranial meninges?. Int J Radiat Oncol Biol Phys 1995, 32(1):241-244.
42. Lal P., et al. Medulloblastomas: clinical profile, treatment techniques and outcome - an institutional experience. Indian J Cancer 2002, 39(3):97-105.
43. Meshref M., et al. Effect of prophylactic cranial irradiation dose on CNS relapse, late cognitive decline and learning disabilities in children treated for acute lymphoblastic leukemia. J Clin Oncol 2006, 24:9032.
44. Weiss E., et al. Does the standardized helmet technique lead to adequate coverage of the cribriform plate? An analysis of current practice with respect to the ICRU 50 report. Int J Radiat Oncol Biol Phys 2001, 49(5):1475-1480.
45. DeAngelis L.M. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol 1998, 38(2-3):245-252.
46. Souchon R., et al. Clinical recommendations of DEGRO and AGO on preferred standard palliative radiotherapy of bone and cerebral metastases, metastatic spinal cord compression, and leptomeningeal carcinomatosis in breast cancer. Breast Care (Basel) 2010, 5(6):401-407.
47. Gani C., et al. Outcome after whole brain radiotherapy alone in intracranial leptomeningeal carcinomatosis from solid tumors. Strahlenther Onkol 2012, 188(2):148-153.
48. Brem S.S., et al. Central nervous system cancers: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005, 3(5):644-690.
49. DeAngelis L.M., Boutros D. Leptomeningeal metastasis. Cancer Invest 2005, 23(2):145-154.
50. Chang E.L., Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003, 8(5):398-410.
51. Chamberlain M.C., Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998, 55(4):506-512.
52. Oechsle K., et al. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol 2010, 136(11):1729-1735.
53. Glantz M.J., et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol 1998, 16(4):1561-1567.
54. Schafer N., et al. Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol 2013, 31(11):e173-e174.
55. Simeone E., et al. Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep 2012, 6:131.
56. Bot I., Blank C.U., Brandsma D. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 2012, 259(9):1976-1978.
57. Postmus P.E., et al. High-dose etoposide for meningeal carcinomatosis in patients with small cell lung cancer. Eur J Cancer Clin Oncol 1989, 25(2):377-378.
58. Clarke J.L., et al. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010, 99(2):283-286.
59. Dhruva N., Socinski M.A. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 2009, 27(22):e31-e32.
60. Grommes C., et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011, 13(12):1364-1369.
61. Jackman D.M., et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006, 24(27):4517-4520.
62. Burel-Vandenbos F., et al. EGFR mutation status in brain metastases of non-small cell lung carcinoma. J Neurooncol 2013, 111(1):1-10.
63. Berg S.L., Chamberlain M.C. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 2003, 5(1):29-40.
64. Bokstein F., Lossos A., Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998, 82(9):1756-1763.
65. Boogerd W., et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004, 40(18):2726-2733.
66. Kim S. Liposomes as carriers of cancer chemotherapy. Current status and future prospects. Drugs 1993, 46(4):618-638.
67. Shapiro W.R., Young D.F., Mehta B.M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975, 293(4):161-166.
68. Glantz M.J., et al. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 2010, 116(8):1947-1952.
69. Ongerboer de Visser B.W., et al. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 1983, 33(12):1565-1572.
70. Chamberlain M.C., Kormanik P.A., Glantz M.J. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro Oncol 2001, 3(1):42-45.
71. Lin N., et al. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg 2011, 115(4):730-736.
72. Berger M.S., et al. The risks of metastases from shunting in children with primary central nervous system tumors. J Neurosurg 1991, 74(6):872-877.
73. Lee S.H., et al. Ventriculoperitoneal shunt for hydrocephalus caused by central nervous system metastasis. J Neurooncol 2011, 104(2):545-551.
74. Pace A., Fabi A. Chemotherapy in neoplastic meningitis. Crit Rev Oncol Hematol 2006, 60(3):194-200.
75. Shapiro W.R., et al. Treatment of meningeal neoplasms. Cancer Treat Rep 1977, 61(4):733-743.
76. Giannone L., Greco F.A., Hainsworth J.D. Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986, 4(1):68-73.
77. Boogerd W., et al. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991, 67(6):1685-1695.
78. Gangji D., et al. Leukoencephalopathy and elevated levels of myelin basic protein in the cerebrospinal fluid of patients with acute lymphoblastic leukemia. N Engl J Med 1980, 303(1):19-21.
79. Glantz M.J., et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17(10):3110-3116.
80. Glantz M.J., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5(11):3394-3402.
81. Jaeckle K.A., et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002, 57(3):231-239.
82. Jaeckle K.A., et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001, 84(2):157-163.
83. Schaefer N., et al. Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine. Acta Oncol 2011, 50(8):1260-1262.
84. Jabbour E., et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007, 109(8):3214-3218.
85. Ostermann K., et al. Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol 2011, 103(3):635-640.
86. Chamberlain M.C. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol 2012, 109(1):143-148.
87. Gutin P.H., et al. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 1977, 61(5):885-887.
88. Gutin P.H., et al. Intrathecal N, N', N''-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study. Cancer 1976, 38(4):1471-1475.
89. Blaney S.M., et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 2005, 23(7):1555-1563.
90. Gammon D.C., et al. Intrathecal topotecan in adult patients with neoplastic meningitis. Am J Health Syst Pharm 2006, 63(21):2083-2086.
91. Groves M.D., et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 2008, 10(2):208-215.
92. Chamberlain M.C., Tsao-Wei D.D., Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 2006, 106(9):2021-2027.
93. Bernardi R.J., et al. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol 2008, 62(2):355-361.
94. Rubenstein J.L., et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood 2013, 121(5):745-751.
95. Chamberlain M.C., et al. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 2009, 91(3):271-277.
96. Dumitrescu C., Lossignol D. Intrathecal trastuzumab treatment of the neoplastic meningitis due to breast cancer: a case report and review of the literature. Case Rep Oncol Med 2013, 2013:154674.
97. Zagouri F., et al. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat 2013, 139(1):13-22.
98. Brandt T, Diener HC, Gerloff C. (Hrsg.). Therapie und Verlauf neurologischer Erkrankungen (German Edition). vollst., überarb., u. erw. Aufl., Auflage. 6th ed. Kohlhammer; 2012.